Imitrex (sumatriptan)
Company: GlaxoWellcome
Approval Status: Approved August 1997
Treatment for: migraine headaches
Areas: Neurology
Possible similar drugs: Imitrex Nasal Spray
| General Information | Side Effects | Additional Information |
General Information
Glaxo Wellcome, Inc. has received clearance from the FDA to market the nasal spray form of Imitrex (sumatriptan). Imitrex is the company's innovative therapy for the acute treatment of migraine and is currently available in the U.S. in subcutaneous injection form and tablet form. Imitrex Nasal Spray will be available to consumers by prescription in October.
Side Effects
In clinical trials for Imitrex Nasal Spray 20 mg, the most common side effects included bad/unusual taste, and nausea and/or vomiting. Most side effects are mild and transient.
Additional Information
Imitrex, a nonsedating, nonnarcotic medication, is the only migraine therapy that treats the multiple symptoms characteristic of migraine, including severe recurrent pain usually on one side of the head often accompanied by one or more of the following: nausea, and sensitivity to light and sound. Imitrex is equally effective when taken at any point during a migraine headache.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
